ArticleThe Journal of antimicrobial chemotherapy2026
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular pharmacodynamics of amoxicillin-clavulanic acid for urinary tract infections caused by Escherichia coli.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe main objective of the present work was to dissect the interplay between penicillin-binding protein (PBP) occupancy, ampC transcriptional dynamics, and β-lactamase activity in Pseudomonas aeruginosa.
methodsUsing wild-type PAO1 and isogenic LMW-PBP knockout mutants (PAOΔdacB, PAOΔdacBdacC, and PAOΔdacBdacCpbpG), we assessed ampC induction following exposure to 18 β-lactams and β-lactamase inhibitors. PBP binding (IC50) was quantified via Bocillin-FL labelling. AmpC mRNA levels were measured by qRT-PCR, and β-lactamase activity was determined in crude extracts, periplasmic and extracellular fractions using nitrocefin and cefalotin substrates.
resultsCarbapenems and cefoxitin, the drugs that maximally inhibited PBP4, induced strong ampC transcription and β-lactamase activity, while ceftazidime, aztreonam, and penicillins (PBP3-binding) triggered mRNA upregulation without enzymatic output. Furthermore, LMW-PBP-deficient mutants showed stepwise ampC overexpression (up to ∼7000-fold), but activity increases plateaued after ∼1100-fold, even after a significant mRNA induction following incubation with ceftazidime.
conclusionsThese findings highlight that ampC transcription does not predict functional enzyme levels, especially for PBP3-binding drugs. Full induction appears to require PBP4 targeting and CreBC activation. These findings underscore the need for integrated assessment of PBP IC50, transcription, and enzymatic activity to guide rational β-lactam and β-lactamase inhibitor therapy, and lay the groundwork for future studies on alternative ampC regulatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.